Nonetheless, the data show the safety of NK-1R antagonists and the specificity of the antitumor strategy applied, meaning that using these antagonists could avoid non desirable side-effects in cancer patients—non-desirable effects that are unfortunately observed using chemotherapeutic agents. This evidence concerns the gene TACR1 and cancer.